Table 4.
Performance metrics of IGFBP7 in established BIOSTAT‐CHF risk models
| Model | NRI | IDI | Likelihood ratio test | |||
|---|---|---|---|---|---|---|
| Estimate (SD) | P‐value | Estimate (SD) | P‐value | Estimate | P‐value | |
| Hospitalization + IGFBP7 | 0.038 (0.018) | 0.030 | 0.006 (0.002) | 0.002 | 16.14 | <0.001 |
| All‐cause mortality + IGFBP7 | 0.055 (0.020) | 0.007 | 0.014 (0.002) | <0.001 | 32.07 | <0.001 |
| Combined + IGFBP7 | 0.030 (0.014) | 0.042 | 0.010 (0.002) | <0.001 | 26.25 | <0.001 |
Note: Hospitalization: age, HF hospitalization in previous year, extent of peripheral edema, SBP, eGFR, gender, atrial fibrillation, diabetes mellitus, GDF15, Hb, NTProBNP, and BMI. All‐cause mortality: age, BUN, NTproBNP, Hb, beta‐blocker at baseline, gender, atrial fibrillation, diabetes mellitus, GDF15, and BMI. Combined: age, NTproBNP, Hb, beta‐blocker at baseline, hospitalization in previous year, extent of peripheral oedema, SBP, HDL, sodium, gender, atrial fibrillation, diabetes mellitus, GDF15, and BMI.
Abbreviations: IGFBP7, insulin‐like growth factor binding protein 7; NRI, net reclassification index; IDI, integrated discrimination improvement; SD, standard deviation.